Toxicological evaluation of the anti-malarial herb Cryptolepis sanguinolenta in rodents

Journal of Pharmacology and Toxicology

Volumn 3, Issue 5, 2008, Pages 335-343

  Ansah, Charles ^a   Mfoafo, E A ^a   Woode, E ^a   Opoku Okrah, C ^a   Owiredu, W K B A ^a   Duwiejua, M ^a  

^a KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

Author keywords

Antimalarial; CNS depressant; Cryptolepis sanguinolenta; Haematological parameters; Rodents; Sleeping time

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ANTIMALARIAL AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBON MONOXIDE; CENTRAL DEPRESSANT AGENT; CRYPTOLEPIS SANGUINOLENTA EXTRACT; CYTOCHROME P450; GAMMA GLUTAMYLTRANSFERASE; GLOBULIN; HEMOGLOBIN; HYPNOTIC SEDATIVE AGENT; KETOCONAZOLE; PENTOBARBITAL; PLANT EXTRACT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BINDING ASSAY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CRYPTOLEPIS; CRYPTOLEPIS SANGUINOLENTA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG POTENTIATION; DRUG SOLUTION; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMATOLOGICAL PARAMETERS; HERBAL MEDICINE; KIDNEY MASS; LIVER TOXICITY; LIVER WEIGHT; LOCOMOTION; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; MOUSE; NONHUMAN; ORGAN WEIGHT; PLANT ROOT; PROTEIN BLOOD LEVEL; RAT; SLEEP TIME; SPLEEN WEIGHT; STOMACH; TOXICITY TESTING;

EID: 45749147106     PISSN: 1816496X     EISSN: None     Source Type: Journal    
DOI: 10.3923/jpt.2008.335.343     Document Type: Article

References (30)

1. Ansah, C. and N.J. Gooderham, 2002. The popular herbal antimalarial, extract of Cryptolepis sanguinolenta, is potently cytotoxic. Toxicol. Sci., 70 (2): 245-251.
2. Ansah, C. and N.J Gooderham, 2005. Reactive oxygert species is associated with cryptolepine cytotoxicity. J. Sci. Technol., 25 (1): 1-10.
3. Bamgbose, S.O.A. and B.K. Noamesi, 1981. Studies on cryptolepine II: Inhibition of carageenan-induced oedema by cryptolepine. Planta Med., 41 (4): 392-396.
4. Bateman, J., R.D. Chapman and D. Simpson, 1998. Possible toxicity of herbal medicines. Scott-Med. J., 43 (1): 7-15.
5. Bierer, Dr.E., L.G. Dubenko, P. Zhang, Q. Lu, P.A. Imbach, A.W. Garofalo, P.W. Phuan, D.M. Fort, J. Litvak, R.E.: Gerber, B. Sloan, J. Luo, R. Cooper and G.M. Reaven, 1998. Antihyperglycaemic activities of cryptolepine analogues: An ethnobotanical lead structure isolated from Cryptolepis sanguinolenta. J. Med. Chem., 41 (15): 2754-2764.
6. Boakye Yiadom, K. and S.M. Herman-Ackah, 1979. Cryptolepine hydrochloride effect on Staphylococcus aureus. J. Pharm. Sci., 68 (12): 1510-1514.
7. Bonjean, K., M.C. Depauw.-Gillet ahd M.P. Defresne, 1998. The DNA intercalating alkaloid Cryptolepine interacts with topoisomerase II and inhibits primarily DNA synthesis in B16 melanoma cells. Biochemistry, 37 (5): 5136-5146.
8. Boye, G.L. and O. Ampofo, 1983. Clinical Uses of Cryptolepis singuinolenta (Asclepiadaceae). In: Proceeding of the 1st International Symposium on Cryptolepine, Boakye Yiadom, K. and S.O.A. Bamgbose (Eds.). Abstract No. 4, University of Science and Technology, Kumasi, Ghana.
9. Cimanga, K., L. Pieters, M. Claeys, D. Vander Berghe and A.J. Vlietinck, 1991. Biological activities of cryptolepine, an alkaloid from Cryptolepis sanguinolenta. Planta Med., 57 (2): A98-A99.
10. Dassonneville, L., A. Lansiaux, A. Wattelet, N. Wattez, C. Mahieu, S. Van Miert, L. Pieters and C. Bailly, 2000. Cytotoxicity and cell cycle effects of the plant alkaloids cryptolepine and neocryptolepine: Relation to drug-induced apoptosis. Eur. J. Pharmacol., 409 (1): 9-18.
11. De Smet P.G.A.M., 1997. Adverse effects of herbal remedies. Adverse Dnig Reaction Bull., 183 (1): 695-698.
12. Gibson, G.G. and P. Skett, 1994. Introduction to Drug Metabolism 2nd Edn. Chapman and Hall Publishers, London, pp: 223-224.
13. Kirby, G.C., A. Paine, D.C. Warhurst, B.K. Noamesi and J.D. Phillipson, 1995. In vitro an in vivo antimalarial activity of cryptolepine, a plant-derived indoloquinolone. Phytother. Res., 9 (5): 359-363.
14. Lisgarten, J.N., M. Coll, J. Portugal, C.W. Wright and J. Aymami, 2002. The antimalarial and cytotoxic drug cryptolepine intercalates into DNA at cytosine-cytosine sites. Nat. Struct. Biol., 9 (1): 57-60.
15. Lowry, O.-H. N.J. Rosebrough, A.L. Farr and R.J. Randall, 1951. Protein measurement with the folin phenol reagent. J. Biol. Chem., 193 (4): 265-275.
16. Mockenhaupt, F.P., S. Ehrhardt, T.A. Eggette P. Agana-Nsiire, K. Stollberg, A. Mathieu, M. Markert, R.N. Otchwemah and U. Bienzle, 2005. Chloroquine-treatment failure in Northern Ghana. Roles of pfcrt T76 and pfmdr1 Y86. Am. Trop. Med. Parasitol., 99 (8): 723-732.
17. Moss, T.M., 1998. Herbal medicines in the emergency-a primer for toxicities and treatment J. Emerg. Nurs., 24 (6): 509-513.
18. Mshana, N.R., D.K. Abbiw, E. Addaeh-Mensah, M.R.A. Ahiyi, J.A. Ekpera, E.G. Enow-Drock, Z.O. Gbile, Q.K. Noamesi, M.A. Odei, H. Odunlami, A.A. Oteng-Yeboah, K. Sarpong, A. Sofowora arid A.N. Tackie, 2000. Traditional medicine and Pharmacopoeia. Contribution to the Revision of Ethnobotanical and Floristic Studies in Ghana Organization of African Unity/Scientific, Technical and Research Committee, pp: 473.
19. Mutabingwa, T.K., 2005. Artemisinin-based combination therapies (ACIs): Best hope for malaria treatment but inaccessible to the needy. Acta Trop., 95 (3): 305-315.
20. Noamesi, B.K. and S.O.A. Bamgbose, 1980. The α-adrenoceptor blocking properties of cryptolpeine on the rat isolated vas. deferens. Planta Med., 39 (1): 51-56.
21. Noamesi, B.K., A. Paine, G.C. Kirby, D.C. Warburst and G.D. Philipson, 1991. In vitro anti-malarial action of cryptolepine, an indoloquinoline. Trans. R. Soc. Trop. Med. Hyg., 85 (1): 315.
22. Omura, T. and R. Sato, 1964. The carbon monoxide-binding pigment of liver microsomes. J. Biol. Chem., 239 (7): 2370-2378.
23. Oyekan, A.O. ano J.P.O. Okafor, 1989. Effects of cryptolepine alone and in combination with dipyridamole on a mouse model of arterial thrombosis. J. Ethnopharmacol., 27 (1-2): 141-148.
24. Oyekan, A.O., 1994. Role of endothelium and cyclic GMP on renal vasodilator responses to cryptolepine in rats. J. Cardiovas. Pharmacol., 23 (4): 602-611.
25. Paulo, A., A. Duarte and E.T. Gomes, 1994. In vitro anti-bacterial screening of Cryptolepis sanguinolenta alkaloids. J. Ethnopharmacol., 44 (2): 127-130.
26. Perharic, L., D. Shaw, C. Leon, P.A. De-Smet and V. S. Murray, 1995. Possible association of liver damage with the use of Chinese herbal medicine for skin disease. Vet. Hum. Toxicol., 37 (6): 562-566.
27. Rauwald, H.W., M. Kober, E. Mutschler and G. Lambrecht, 1992. Antimuscarinic properties of cryptolepine and the alkaloid fraction at M1, M2 and M3 receptors. Planta Med., 58 (6): 486-488.
28. Sawer I.K., M.I. Berry, M.W. Brown and J.L. Ford, 1995. The effect of cryptolepine on the morphology and survival of Escherichia coli and Candida albicans and Saccharomyces cerevisiae. J. Applied Bacteriol., 79 (3): 314-321.
29. WHO, 2003. Shaping the Future: The World Health Report 2003. Report of WHO Scientific Group. Technical Report Series 711, Geneva, Switzerland.
30. Wright, C.W., J. Addae-Kyereme, A.G. Breen, J.E. Brown, M.F. Cox, S.L. Croft, Y. Gokcek, H. Kendrick, R.M. Phillips and P.L. Pollet 2001. Synthesis and evaluation of cryptolepine analogues for their potential as antimalarial agents. J. Med. Chem., 44 (19): 3187-3194.